{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:24:10Z","timestamp":1783347850977,"version":"3.54.6"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1245\/s10434-026-19829-1","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:31:14Z","timestamp":1779197474000},"page":"7520-7526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time Bias on Survival"],"prefix":"10.1245","volume":"33","author":[{"given":"Amir","family":"Ashraf Ganjouei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laleh","family":"Foroutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Romero","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzo","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Nakakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Corvera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Alseidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Abdelgadir","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"1","key":"19829_CR1","doi-asserted-by":"publisher","first-page":"16425","DOI":"10.1038\/s41598-020-73525-y","volume":"10","author":"A Bengtsson","year":"2020","unstructured":"Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci Rep. 2020;10(1):16425. https:\/\/doi.org\/10.1038\/s41598-020-73525-y.","journal-title":"Sci Rep."},{"issue":"10","key":"19829_CR2","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.3390\/cancers14102417","volume":"14","author":"\u00c1 Sally","year":"2022","unstructured":"Sally \u00c1, McGowan R, Finn K, Moran BM. Current and future therapies for pancreatic ductal adenocarcinoma. Cancers (Basel). 2022;14(10):2417. https:\/\/doi.org\/10.3390\/cancers14102417.","journal-title":"Cancers (Basel)."},{"issue":"4","key":"19829_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma version 2.2021, NCCN clinical practice guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(4):439\u201357. https:\/\/doi.org\/10.6004\/jnccn.2021.0017.","journal-title":"J Natl Compr Canc Netw."},{"issue":"3","key":"19829_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","volume":"9","author":"KJ Labori","year":"2024","unstructured":"Labori KJ, Bratlie SO, Andersson B, et al. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2024;9(3):205\u201317. https:\/\/doi.org\/10.1016\/S2468-1253(23)00405-3.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"7","key":"19829_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1308\/rcsann.2019.0060","volume":"101","author":"K Rangarajan","year":"2019","unstructured":"Rangarajan K, Pucher PH, Armstrong T, Bateman A, Hamady Z. Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis. Ann R Coll Surg Engl. 2019;101(7):453\u201362. https:\/\/doi.org\/10.1308\/rcsann.2019.0060.","journal-title":"Ann R Coll Surg Engl."},{"issue":"4","key":"19829_CR6","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1245\/s10434-019-08087-z","volume":"27","author":"A Chawla","year":"2020","unstructured":"Chawla A, Molina G, Pak LM, et al. Neoadjuvant therapy is associated with improved survival in borderline-resectable pancreatic cancer. Ann Surg Oncol. 2020;27(4):1191\u2013200. https:\/\/doi.org\/10.1245\/s10434-019-08087-z.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"19829_CR7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jama.2020.9151","volume":"325","author":"K Yadav","year":"2021","unstructured":"Yadav K, Lewis RJ. Immortal time bias in observational studies. JAMA. 2021;325(7):686\u20137. https:\/\/doi.org\/10.1001\/jama.2020.9151.","journal-title":"JAMA."},{"issue":"11","key":"19829_CR8","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1158\/1055-9965.EPI-22-0495","volume":"31","author":"ED Duchesneau","year":"2022","unstructured":"Duchesneau ED, Jackson BE, Webster-Clark M, et al. The timing, the treatment, the question: comparison of epidemiologic approaches to minimize immortal time bias in real-world data using a surgical oncology example. Cancer Epidemiology, Biomarkers & Prevention. 2022;31(11):2079\u201386. https:\/\/doi.org\/10.1158\/1055-9965.EPI-22-0495.","journal-title":"Cancer Epidemiology, Biomarkers & Prevention."},{"issue":"23","key":"19829_CR9","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","volume":"31","author":"A Giobbie-Hurder","year":"2013","unstructured":"Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol. 2013;31(23):2963\u20139. https:\/\/doi.org\/10.1200\/JCO.2013.49.5283.","journal-title":"J Clin Oncol."},{"key":"19829_CR10","doi-asserted-by":"publisher","first-page":"1157706","DOI":"10.3389\/fmed.2023.1157706","volume":"10","author":"Q Zheng","year":"2023","unstructured":"Zheng Q, Otahal P, Cox IA, et al. The influence of immortal time bias in observational studies examining associations of antifibrotic therapy with survival in idiopathic pulmonary fibrosis: A simulation study. Front Med. 2023;10:1157706. https:\/\/doi.org\/10.3389\/fmed.2023.1157706.","journal-title":"Front Med."},{"key":"19829_CR11","unstructured":"American College of Surgeons, Commission on Cancer. National Cancer Database (NCDB). Published 2024. Accessed January 29, 2025. https:\/\/www.facs.org\/quality-programs\/cancer-programs\/national-cancer-database\/"},{"key":"19829_CR12","doi-asserted-by":"publisher","unstructured":"Yang G, Burgess S, Schooling CM. Illustrating the structures of bias from immortal time using directed acyclic graphs. arXiv. Preprint posted online January 9, 2024. https:\/\/doi.org\/10.48550\/arXiv.2312.06155","DOI":"10.48550\/arXiv.2312.06155"},{"issue":"1","key":"19829_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ijrobp.2019.07.056","volume":"106","author":"NB Newman","year":"2020","unstructured":"Newman NB, Brett CL, Kluwe CA, et al. Immortal time bias in national cancer database studies. Int J Rad Oncol Biol Phys. 2020;106(1):5\u201312. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.07.056.","journal-title":"Int J Rad Oncol Biol Phys."},{"issue":"1","key":"19829_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.14376","volume":"60","author":"D Weymann","year":"2025","unstructured":"Weymann D, Krebs E, Regier DA. Addressing immortal time bias in precision medicine: practical guidance and methods development. Health Serv Res. 2025;60(1):e14376. https:\/\/doi.org\/10.1111\/1475-6773.14376.","journal-title":"Health Serv Res."},{"issue":"2","key":"19829_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","volume":"8","author":"P Ghaneh","year":"2023","unstructured":"Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):157\u201368. https:\/\/doi.org\/10.1016\/S2468-1253(22)00348-X.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"3","key":"19829_CR16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","volume":"7","author":"DPS Sohal","year":"2021","unstructured":"Sohal DPS, Duong M, Ahmad SA, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):421\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2020.7328.","journal-title":"JAMA Oncol."},{"issue":"5","key":"19829_CR17","doi-asserted-by":"publisher","first-page":"zrea087","DOI":"10.1093\/bjsopen\/zrae087","volume":"8","author":"D Aliseda","year":"2024","unstructured":"Aliseda D, Mart\u00ed-Cruchaga P, Zozaya G, et al. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials. BJS Open. 2024;8(5):zrea087. https:\/\/doi.org\/10.1093\/bjsopen\/zrae087.","journal-title":"BJS Open."},{"issue":"6","key":"19829_CR18","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1245\/s10434-024-16674-y","volume":"32","author":"AHY Chan","year":"2025","unstructured":"Chan AHY, Zhao Y, Tan HL, et al. Clinical outcomes of neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: systematic review and meta-analysis of latest randomized controlled trials. Ann Surg Oncol. 2025;32(6):4094\u2013107. https:\/\/doi.org\/10.1245\/s10434-024-16674-y.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"19829_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/SLA.0000000000005925","volume":"279","author":"T Sugawara","year":"2024","unstructured":"Sugawara T, Rodriguez Franco S, Sherman S, et al. Neoadjuvant chemotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: an updated nationwide study. Ann Surg. 2024;279(2):331\u20139. https:\/\/doi.org\/10.1097\/SLA.0000000000005925.","journal-title":"Ann Surg."},{"issue":"2","key":"19829_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/sj.bjc.6604838","volume":"100","author":"JP Neoptolemos","year":"2009","unstructured":"Neoptolemos JP, Stocken DD, Tudur Smith C, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer. 2009;100(2):246\u201350. https:\/\/doi.org\/10.1038\/sj.bjc.6604838.","journal-title":"Br J Cancer."},{"issue":"4","key":"19829_CR21","doi-asserted-by":"publisher","first-page":"663","DOI":"10.21037\/jgo.2019.02.09","volume":"10","author":"R Shridhar","year":"2019","unstructured":"Shridhar R, Takahashi C, Huston J, Meredith KL. Neoadjuvant therapy and pancreatic cancer: a national cancer database analysis. J Gastrointest Oncol. 2019;10(4):663\u201373. https:\/\/doi.org\/10.21037\/jgo.2019.02.09.","journal-title":"J Gastrointest Oncol."},{"issue":"18","key":"19829_CR22","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.3390\/cancers13184724","volume":"13","author":"A Lambert","year":"2021","unstructured":"Lambert A, Schwarz L, Ducreux M, Conroy T. Neoadjuvant treatment strategies in resectable pancreatic cancer. Cancers (Basel). 2021;13(18):4724. https:\/\/doi.org\/10.3390\/cancers13184724.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"19829_CR23","doi-asserted-by":"publisher","first-page":"18278","DOI":"10.1038\/s41598-020-74067-z","volume":"10","author":"Y Matsuda","year":"2020","unstructured":"Matsuda Y, Ohkubo S, Nakano-Narusawa Y, et al. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems. Sci Rep. 2020;10(1):18278. https:\/\/doi.org\/10.1038\/s41598-020-74067-z.","journal-title":"Sci Rep."},{"issue":"1","key":"19829_CR24","doi-asserted-by":"publisher","first-page":"13592","DOI":"10.1038\/s41598-022-17743-6","volume":"12","author":"PLS Uson Junior","year":"2022","unstructured":"Uson Junior PLS, Carvalho L, Fernandes MLC, et al. Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis. Sci Rep. 2022;12(1):13592. https:\/\/doi.org\/10.1038\/s41598-022-17743-6.","journal-title":"Sci Rep."},{"issue":"4","key":"19829_CR25","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1111\/1475-6773.12020","volume":"48","author":"JM Brooks","year":"2013","unstructured":"Brooks JM, Ohsfeldt RL. Squeezing the balloon: propensity scores and unmeasured covariate balance. Health Serv Res. 2013;48(4):1487\u2013507. https:\/\/doi.org\/10.1111\/1475-6773.12020.","journal-title":"Health Serv Res."},{"issue":"6","key":"19829_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.16199","volume":"5","author":"A Klein-Brill","year":"2022","unstructured":"Klein-Brill A, Amar-Farkash S, Lawrence G, Collisson EA, Aran D. Comparison of FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line chemotherapy for metastatic pancreatic ductal adenocarcinoma. JAMA Netw Open. 2022;5(6):e2216199. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.16199.","journal-title":"JAMA Netw Open."},{"issue":"8","key":"19829_CR27","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1001\/jamaoncol.2024.1575","volume":"10","author":"M Cecchini","year":"2024","unstructured":"Cecchini M, Salem RR, Robert M, et al. Perioperative Modified FOLFIRINOX for resectable pancreatic cancer: a nonrandomized controlled trial. JAMA Oncol. 2024;10(8):1027\u201335. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1575.","journal-title":"JAMA Oncol."},{"issue":"23","key":"19829_CR28","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.3748\/wjg.v25.i23.2839","volume":"25","author":"F Yang","year":"2019","unstructured":"Yang F, Jin C, Fu DL, Warshaw AL. Modified FOLFIRINOX for resected pancreatic cancer: opportunities and challenges. World J Gastroenterol. 2019;25(23):2839\u201345. https:\/\/doi.org\/10.3748\/wjg.v25.i23.2839.","journal-title":"World J Gastroenterol."},{"issue":"1","key":"19829_CR29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.21037\/tlcr-24-1002","volume":"14","author":"KM Tsuruda","year":"2025","unstructured":"Tsuruda KM, Hektoen HH, Costa DR, Andreassen BK. Immortal time bias in survival outcomes when comparing treatment with chemotherapy versus immunochemotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2025;14(1):300\u20132. https:\/\/doi.org\/10.21037\/tlcr-24-1002.","journal-title":"Transl Lung Cancer Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19829-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19829-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19829-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:41:19Z","timestamp":1783345279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19829-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["19829"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19829-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no commercial or financial conflicts of interest related to this study. No external funding or material support was received for this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}